Send your comments and tips to whitecoat@globe.com
  Awards Beth Israel Deaconess Medical Ctr. Boston Medical Center Boston University Brigham and Women's Hospital Broad Institute Cambridge Health Alliance Caritas St. Elizabeth's Medical Ctr. Children's Hospital Boston Dana-Farber Cancer Institute Grants Harvard University Joslin Diabetes Center Lahey Clinic Mass. General Hospital Mass. Health Law McLean Hospital MIT New England Baptist Hospital Personnel Moves Public Health Research Short White Coat Tufts-New England Medical Center Tufts University UMass Memorial Medical Center University of Massachusetts VA Medical Centers    A Healthy Blog Running A Hospital Nature Network Boston SciBos - Corie Lok's blog Kevin, M.D. Blog, MD Dr. Flea's blog Nurse at small Your Child's Health Blog Healthy Children blog WBUR's CommonHealth Other Globe Blogs
Elizabeth Cooney is a health reporter for the Worcester Telegram &
Gazette.
Boston Globe Health and Science staff:
Scott Allen Alice Dembner Carey Goldberg Liz Kowalczyk Stephen Smith Colin Nickerson Beth Daley Karen Weintraub, Deputy Health and Science Editor, and Gideon Gil, Health and Science Editor. Short White Coat blogger Ishani Ganguli  |
« Boston stroke expertise exported to Seattle | Main | Funding concerns hit some cancer trials » Wednesday, February 7, 2007Today's Globe: overdose questions, Caritas debate, breast cancer relapse test, bleeding drug concernsA doctor's role is questioned in a girl's fatal overdose from powerful prescription drugs fed to her by her parents. Prosecutors would not say whether Dr. Kayoko Kifuji of Tufts-New England Medical Center is a target of a criminal investigation, but have forwarded details from the case to state medical licensing regulators. News that Ascension Health plans to absorb six Caritas Christi hospitals operated by the Archdiocese of Boston triggered a debate yesterday about the future of Catholic healthcare in the region. Mayor Thomas M. Menino expressed trepidation about the fate of two Boston hospitals in the chain, Caritas St. Elizabeth's Medical Center in Brighton and Caritas Carney in Dorchester. The Food and Drug Administration yesterday approved a genetic test that, when conducted soon after a woman learns she has breast cancer, can predict the odds of the disease returning and worsening. The test, called MammaPrint, analyzes tissue from a breast tumor to gauge the activity of 70 key genes and determines the likelihood of the cancer's recurrence. A drug widely used to prevent excessive bleeding during heart surgery appears to raise the risk of dying in the five years afterward by nearly 50 percent, an international study found. The researchers said replacing the drug -- aprotinin, sold by Bayer AG under the brand name Trasylol -- with other, less expensive medications for a year would prevent 10,000 deaths worldwide over the next five years. Posted by Elizabeth Cooney at 06:15 AM
|
